Prolong Pharmaceuticals Overview
- Year Founded
-
2003
- Status
-
Private
- Employees
-
29
- Latest Deal Type
-
2ndary - Private
Prolong Pharmaceuticals General Information
Description
Developer of biopharmaceutical products designed to treat several diseases and their debilitating comorbidities. The company's products facilitate the transfer of oxygen to oxygen-deprived cells and tissues and down-regulates the inflammatory response in blood samples of patients with sickle cell disease (SCD) and other disorders caused by anemia, hypoxia, or ischemia, thereby enabling healthcare practitioners to improve the quality of life with significant mortality and engage in the development of hematology and oncology products.
Contact Information
Website
www.prolongpharma.comCorporate Office
- 300 Corporate Court
- Suite B
- South Plainfield, NJ 07080
- United States
Corporate Office
- 300 Corporate Court
- Suite B
- South Plainfield, NJ 07080
- United States
Prolong Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Secondary Transaction - Private | 01-Feb-2022 | Completed | Clinical Trials - Phase 2 | |||
| 4. Debt - PPP | 04-Apr-2020 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC (Series C) | 14-Aug-2010 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series A) | 05-Apr-2005 | $500K | $725K | Completed | Startup | |
| 1. Early Stage VC (Series A) | 31-Mar-2003 | $225K | $225K | Completed | Startup |
Prolong Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Prolong Pharmaceuticals Patents
Prolong Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026107268-A1 | A packing apparatus for improving the stability of peg-hemoglobin | Pending | 15-Nov-2024 | ||
| US-20260335415-A1 | Dosing regimen of pegylated hemoglobin | Pending | 17-Apr-2024 | ||
| WO-2025222053-A1 | Improved dosing regimen of pegylated hemoglobin | Pending | 17-Apr-2024 | ||
| WO-2025222059-A1 | Method of treating cancer using pegylated bovine hemoglobin | Pending | 17-Apr-2024 | ||
| AU-2023358521-A1 | A stable hemoglobin protein composition | Pending | 14-Oct-2022 | C07K14/805 |
Prolong Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Prolong Pharmaceuticals FAQs
-
When was Prolong Pharmaceuticals founded?
Prolong Pharmaceuticals was founded in 2003.
-
Where is Prolong Pharmaceuticals headquartered?
Prolong Pharmaceuticals is headquartered in South Plainfield, NJ.
-
What is the size of Prolong Pharmaceuticals?
Prolong Pharmaceuticals has 29 total employees.
-
What industry is Prolong Pharmaceuticals in?
Prolong Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Prolong Pharmaceuticals a private or public company?
Prolong Pharmaceuticals is a Private company.
-
What is Prolong Pharmaceuticals’s current revenue?
The current revenue for Prolong Pharmaceuticals is .
-
How much funding has Prolong Pharmaceuticals raised over time?
Prolong Pharmaceuticals has raised $30.7M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
